1.
Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years: Long-term Follow-up from The 'Bevacizumab in Trabeculectomy Study'.
John Landers, Sean Mullany, Mark M Hassall, Jamie E Craig
OphthalmologyMay 20260 citationsRandomized Controlled Trial
A study found a single intravitreal bevacizumab dose during trabeculectomy with MMC improved surgical success and reduced medication needs for 3 years, offering a new adjunct for glaucoma surgery.